

UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

COMMISSIONER OF PATENTS AND TRADEMARKS Address: Washington, D.C. 20231

ATTORNEY DOCKET NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. DEGLI-ES

10/03/27 08/943,7/6

HM32/1027

LAW DEPARTMENT IMMUNEX CORPORATION 51 UNIVERSITY STREET SEATTLE WA 98101

	EXAMINER
しょうかい	- ''
1 / 7/11/1	
1 1 1 1 1 1 1 1	With the first time to the second

PAPER NUMBER **ART UNIT**

10/27/99 DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

Office Action Summary

Application No. 08/943,776 Applicant(s)

Degli-Esposti

Examiner

Eliane Lazar-Wesley

Group Art Unit 1646



X Responsive to communication(s) filed on Dec 24, 1998	
☑ This action is FINAL.	
Since this application is in condition for allowance except for for in accordance with the practice under Ex parte Quayle, 1935 C.I.	· ·
A shortened statutory period for response to this action is set to expis longer, from the mailing date of this communication. Failure to reapplication to become abandoned. (35 U.S.C. § 133). Extensions of 37 CFR 1.136(a).	espond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s) 20 and 21	is/are withdrawn from consideration.
	is/are allowed.
X Claim(s) 1, 3, 6, 7, 10, 11, 13, 14, 16, and 17	
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing Re	view. PTO-948.
☐ The drawing(s) filed on is/are objected t	
☐ The proposed drawing correction, filed on	
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
☐ Acknowledgement is made of a claim for foreign priority under	er 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the	
received.	
received in Application No. (Series Code/Serial Number	·)
$\hfill\Box$ received in this national stage application from the Inte	rnational Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priority un	nder 35 U.S.C. § 119(e).
Attachment(s)	
☑ Notice of References Cited, PTO-892	
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s).	·
☐ Interview Summary, PTO-413	
 □ Notice of Draftsperson's Patent Drawing Review, PTO-948 □ Notice of Informal Patent Application, PTO-152 	

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Application/Control Number: 08/943,776

Art Unit: 1646

DETAILED ACTION

1. The amendment filed December 24, 1998, has been entered.

Claims 4, 5 and 18 have been canceled.

Claims 1-3, 16 and 17 have been amended, and new claims 22-25 have been added.

Claim Objections

2. Claims 8, 9, 12, 15 and 19 are objected to as dependent of canceled claims 4, 5 and 18.

Claim Rejections - 35 USC § 112

3. Claims 1, 3, 16, 17 and the dependent claims 6, 7, 10, 11, 13, 14 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 16 remain indefinite because, in c), they recite hybridization conditions, without reciting the wash conditions. Applicants argue that the Examiner's position relevant to the importance of wash conditions is improper, and Applicants request the Examiner to provide scientifically sound documentation. Maniatis et al., Molecular Cloning, A laboratory manual, Cold Spring Harbor Laboratory, 1982, Vol. II, pages 324-325, discusses factors involved in hybridization conditions, and among them discusses the stringency of washing following hybridization, reciting that the washing conditions should be as stringent as possible, which supports the Examiner's position about the criticality of wash conditions.

Application/Control Number: 08/943,776

Art Unit: 1646

Claim 1 remains further rejected because, in d), it recites biologically active fragments of

proteins, without reciting which activity. As stated in the former office action, biologically active

fragments would also embrace epitopes for antibodies, that could not be used in accordance with the

invention.

Claims 3 and 17 remain indefinite with respect of the percent identity for the reasons of

record. While Applicants recite in the claims the use of the GAP computer program for determining

identity, they do not provide in the claims or in the specification (page 9, lines 26-28), the parameters

used to perform the sequence alignment, like gap penalties, mismatch penalties.

4. The claims are free of the prior art.

5. Claims 2 and 22-25 are allowable.

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy

as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS

from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the

mailing date of this final action and the advisory action is not mailed until after the end of the

THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the

date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be

calculated from the mailing date of the advisory action. In no event, however, will the statutory

period for reply expire later than SIX MONTHS from the mailing date of this final action.

Page 3

Art Unit: 1646

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eliane Lazar-Wesley, PhD, whose telephone number is (703) 305 4059. The examiner can normally be reached on Monday-Friday from 8:30am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lila Feisee, can be reached on (703) 308-2731.

Official papers filed by fax should be directed to (703) 308 4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ELW March 12, 1999

FW

Prema Ment-PREMA MERTZ PRIMARY EXAMINER